Image placeholder title

Mobocertinib Treatment for Non-Small Cell Lung Cancer with exon 20 Mutations

FDA grants breakthrough therapy status to Mobocertinib for treatment of patients with NSCLC and exon 20 mutations.

Image placeholder title

Alunbrig for ALK Positive Non Small Cell Lung Cancer

Alunbrig Continues to Demonstrate Superiority in the First - Line After Two Years of Follow-Up for ALK + NSCLC

Image placeholder title

Amivantamab Treatment of EGFR Positive Non-Small Cell Lung Cancer

Amivantamab targets Non-Small Cell Lung Cancer with cancer causing EGFR Exon 20 Insertion Mutations